Prediction of the Risk of Bleeding During Anticoagulant Treatment for Venous Thromboembolism

Abstract
CURRENTLY, the range of indications for the use of anticoagulant therapy is steadily growing. There is now evidence from clinical trials that anticoagulant therapy is effective in the primary and secondary prevention of thromboembolic complications in patients with atrial fibrillation, prosthetic heart valves, cardioembolic ischemic cerebral disease, myocardial infarction, and venous thromboembolism (VTE).1